Lee-May Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lee-May Chen has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jocelyn Chapman
University of California, San Francisco 2 Helen Diller Family Comprehensive Cancer Center San Francisco, California
12 shared publications - David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
9 shared publications - Andrea Milbourne
The University of Texas MD Anderson Cancer Center, Houston, Texas
8 shared publications David S. Loose
8 shared publications- Graciela M. Nogueras Gonzalez
Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
8 shared publications Henry Lynch
8 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (5) , e70104
The new (version 9) American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging protocol for carcinoma of the vulva
The American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging for all cancer sites has been updated periodically as a published manual for many years. The last update of the manual version, the eighth edition AJCC Cancer Staging Manual , went into use on January 1, 2018. The AJCC has since restructured and updated its processes for curating, analyzing, and publishing updates to the TNM staging system. All AJCC staging‐related data are now housed on its new application programming interface. Consequently, the subsequent AJCC TNM staging updates are now published electronically as protocols and are released by disease sites. The protocol for carcinoma of the vulva, AJCC version 9, is now published. The new TNM vulvar cancer staging was validated using the American College of Surgeons’ National Cancer Data Base. This article highlights the changes to the new AJCC TNM staging protocol for carcinoma of the vulva; these changes align with the 2021 International Federation for Gynecology and Obstetrics staging. The most important of the changes are: (1) a new method for depth of invasion measurement, (2) the addition of a new T subcategory—T4, (3) redefined N subcategories, and (4) an increased number of M subcategories with the addition of clinical to all M subcategories.
- 28 August 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (5) , e70104
Open AccessThe new (version 9) American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging protocol for carcinoma of the vulva
The American Joint Committee on Cancer (AJCC) tumor‐node‐metastasis (TNM) staging for all cancer sites has been updated periodically as a published manual for many years. The last update of the manual version, the eighth edition AJCC Cancer Staging Manual , went into use on January 1, 2018. The AJCC has since restructured and updated its processes for curating, analyzing, and publishing updates to the TNM staging system. All AJCC staging‐related data are now housed on its new application programming interface. Consequently, the subsequent AJCC TNM staging updates are now published electronically as protocols and are released by disease sites. The protocol for carcinoma of the vulva, AJCC version 9, is now published. The new TNM vulvar cancer staging was validated using the American College of Surgeons’ National Cancer Data Base. This article highlights the changes to the new AJCC TNM staging protocol for carcinoma of the vulva; these changes align with the 2021 International Federation for Gynecology and Obstetrics staging. The most important of the changes are: (1) a new method for depth of invasion measurement, (2) the addition of a new T subcategory—T4, (3) redefined N subcategories, and (4) an increased number of M subcategories with the addition of clinical to all M subcategories.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures1 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Supplementary Fig 1-9 with legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures1 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Supplementary Fig 1-9 with legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Study Representativeness Table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Study Representativeness Table
- 24 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Purpose: ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). Patients and Methods: This was a phase II, Simon two-stage study with a planned sample size of 29 evaluable patients. Eligible patients had locally advanced or metastatic solid tumors with measurable disease by Response Evaluation Criteria in Solid Tumors 1.1 and radiographic progression at study entry. Patients were required to have ARID1A loss as determined by immunohistochemistry analysis of tumor tissue. Patients received ceralasertib 160 mg twice daily on days 1 to 14 every 28 days. RNA sequencing (RNA-seq) and cyclic immunofluorescence were performed on tumor tissue to identify potential biomarkers of treatment response. Results: The confirmed objective response rate (ORR) was 14% among the 29 efficacy-evaluable patients. All four responses, including three complete responses, occurred in endometrioid endometrial carcinoma or ovarian clear-cell carcinoma, with an ORR of 33% and a median duration of response of 33.7 months in this subset. Including one patient with uterine carcinosarcoma who had stable disease, the ORR was 31% among the 13 patients with gynecologic malignancies. Exploratory RNA-seq analysis of pretreatment archival tumor tissue identified upregulated G2–M checkpoint and DNA double-strand break-sensing pathways in patients who responded. Immune profiling revealed tumor immune microenvironment changes associated with the response to ceralasertib. Conclusions: Ceralasertib monotherapy demonstrated promising antitumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATRis in this patient population.
- 24 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Purpose: ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). Patients and Methods: This was a phase II, Simon two-stage study with a planned sample size of 29 evaluable patients. Eligible patients had locally advanced or metastatic solid tumors with measurable disease by Response Evaluation Criteria in Solid Tumors 1.1 and radiographic progression at study entry. Patients were required to have ARID1A loss as determined by immunohistochemistry analysis of tumor tissue. Patients received ceralasertib 160 mg twice daily on days 1 to 14 every 28 days. RNA sequencing (RNA-seq) and cyclic immunofluorescence were performed on tumor tissue to identify potential biomarkers of treatment response. Results: The confirmed objective response rate (ORR) was 14% among the 29 efficacy-evaluable patients. All four responses, including three complete responses, occurred in endometrioid endometrial carcinoma or ovarian clear-cell carcinoma, with an ORR of 33% and a median duration of response of 33.7 months in this subset. Including one patient with uterine carcinosarcoma who had stable disease, the ORR was 31% among the 13 patients with gynecologic malignancies. Exploratory RNA-seq analysis of pretreatment archival tumor tissue identified upregulated G2–M checkpoint and DNA double-strand break-sensing pathways in patients who responded. Immune profiling revealed tumor immune microenvironment changes associated with the response to ceralasertib. Conclusions: Ceralasertib monotherapy demonstrated promising antitumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATRis in this patient population.
- Open Access
- 22 September 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 176, S2
GOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study (001)
- 22 September 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 176, S2
Open AccessGOG 3026 A phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: A GOG foundation study (001)
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S29-S30
57 A roadmap to safety: decreased intraoperative injury with a multidisciplinary approach to placenta accreta
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S29-S30
Open Access57 A roadmap to safety: decreased intraoperative injury with a multidisciplinary approach to placenta accreta
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S25
48 An evidence-based approach to prescribing post-discharge opioids after laparotomy
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S25
Open Access48 An evidence-based approach to prescribing post-discharge opioids after laparotomy